APOE and Alzheimer disease: They found that only 36% of psychiatrists believed their services could adapt to deliver DMTs within a year and only 6% of psychiatry services fully comply with NICE guidelines in accessing additional biomarker and diagnostic tests for AD.16 There are prerequisites such as the integration of genetic testing into the diagnostic pathway, due to a higher prevalence of ARIA following anti-amyloid MAB administration in homozygous APOE ε4 allele carriers.4 DMTs also necessitate regular drug administration and monitoring for side-effects.